University of Pisa
Pisa, Pisa, Italy
Marta Mosca is Professor of Rheumatology at the University of Pisa and Head of the Rheumatology Unit at the Azienda Ospedaliera Universitaria Pisana, Italy. At the University of Pisa, prof Mosca is also the Director of Fellowship Training Program in Rheumatology. Since December 2016 she is the Coordinator of the European Reference Network on “Rare and Hereditary Connective and Musculoskeletal Diseases” (RECONNET) promoted by the European Commission.
She was also the coordinator of the European Commission Program INTEGRATE, which aims at integrating the physician and the patients’ point of view in SLE. Professor Mosca is a member of the Scientific Advisory Board of LUPUS EUROPE.
Since November 2019 she is member of the Systemic Lupus Erythematosus International Collaborating Clinics Group. Professor Mosca has participated in the development of EULAR recommendations for the management of SLE, for women’s health, for the management of antiphospholipid syndrome in adults, has coordinated the Development of recommendations for monitoring SLE patients in clinical practice and in observational studies. She was a member of the EULAR-ACR steering committee for the development of Classification Criteria for SLE.
Professor Marta Mosca has served as Abstract chair of the 2022 EULAR congress and as Scientific Chair of the 2023 EULAR Congress.
0284: Phenotyping Calcinosis: A Rare Manifestation of Rare Diseases
Sunday, November 12, 2023
9:00 AM – 11:00 AM PT
Disclosure(s): AstraZeneca: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Otsuka: Consultant (Ongoing); UCB: Consultant (Ongoing)
Sunday, November 12, 2023
9:00 AM – 11:00 AM PT
Disclosure(s): AstraZeneca: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Otsuka: Consultant (Ongoing); UCB: Consultant (Ongoing)
Meet the Panel: The Latest in Lupus Treatment
Monday, November 13, 2023
7:30 AM – 8:15 AM PT
Disclosure(s): AstraZeneca: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Otsuka: Consultant (Ongoing); UCB: Consultant (Ongoing)
Monday, November 13, 2023
9:00 AM – 11:00 AM PT
Disclosure(s): AstraZeneca: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Otsuka: Consultant (Ongoing); UCB: Consultant (Ongoing)
Tuesday, November 14, 2023
9:00 AM – 11:00 AM PT
Disclosure(s): AstraZeneca: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Otsuka: Consultant (Ongoing); UCB: Consultant (Ongoing)
Tuesday, November 14, 2023
9:00 AM – 11:00 AM PT
Disclosure(s): AstraZeneca: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Otsuka: Consultant (Ongoing); UCB: Consultant (Ongoing)
Tuesday, November 14, 2023
9:00 AM – 11:00 AM PT
Disclosure(s): AstraZeneca: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Otsuka: Consultant (Ongoing); UCB: Consultant (Ongoing)